Skip to main content

Table 1 Characteristics of 495 patients who received prophylaxis and 165 patients who did not receive prophylaxis

From: Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy

Characteristics Primary prophylaxis Secondary prophylaxis No prophylaxis
  CD4 <200/μL CD4 ≧200/μL P value CD4 <200/μL CD4 ≧200/μL P value  
Patient number, n 211 68   145 71   165
Age at enrollment, mean (SD), y 39.0 (12.0) 35.0 (10.7) 0.03 38.6 (10.2) 35.0 (8.4) 0.006 37.0 (10.9)
Male sex, n (%) 195 (92.4) 66 (97.1) 0.26 134 (92.4) 68 (95.8) 0.56 152 (92.1)
Risk behaviors, no (%)        
   MSM 138 (65.4) 48 (70.6) 0.74 89 (61.4) 58 (81.7) 0.22 110 (66.7)
   Heterosexual 68 (32.2) 17 (25.0) 0.47 50 (34.5) 10 (14.1) 0.02 41 (24.8)
   Others 5 (2.4) 3 (4.4) 0.41 6 (4.1) 3 (4.2) 0.99 14 (8.5)
Nadir CD4 count, median (range), cells/μL 27 (1-182) 93 (67-194) <0.001 17 (0-165) 40 (1-174) <0.001 134 (4-199)
Baseline PVL, median (range), log10 copies/ml 5.46 (2.60-6.12) 5.60 (2.60-6.19) 0.13 5.56 (2.60-5.99) 5.72 (3.09-5.98) 0.04 5.14 (2.60-5.88)
Chemoprophylaxis, n (%)        
   Trimethoprim-sulfamethoxazole 207 (98.1) 67 (98.5) 1 142 (97.9) 71 (100) 1 NA
   Clindamycin/primaquine 2 (0.9) 2 (2.9) 0.26 29 (20.0) 15 (21.1) 0.86 NA
   Macrolides 16 (9.0) 5 (7.4) 1 6 (4.1) 7 (9.9) 0.14 NA
Duration of prophylaxis, median (range), m 2.0 (0.2-66.2) 5.3 (0.25-47.8) 0.036 2.7 (0.1-62) 4.0 (0.34-57) 0.04  
CD4 at discontinuation of prophylaxis        
   median (range), cells/ul 101 (2-199) 234 (207-642) <0.001 111 (5-197) 279 (201-880) <0.001  
   <100 cells/ul, n (%) 101 (47.9) 0 (0)   53 (36.6) 0 (0)   
PVL at discontinuation of prophylaxis, median (range), log10 copies/ml 2.60 (2.60-5.88) 2.60 (2.60-5.15) 0.027 2.60 (2.60-5.88) 2.60 (2.60-5.51) 0.022 NA
   PVL < 400 copies/ml, no (%) 130 (61.6) 55 (80.9) 0.24 85 (58.6) 53 (74.6) 0.31 NA
Latest CD4, median (range), cells/ul 200 (2-214) 376 (0-952) 0.019 200 (2-215) 426 (2-1124) 0.005 200 (4-209)
   <200 cells/ul, n (%) 78 (37.0) 15 (22) 0.11 41 (28.3) 10 (14.1) 0.09 49 (29.7)
  1. Abbreviations: MSM. Men who have sex with men; NA, not applicable; PVL, plasma HIV RNA load
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us